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Benzodiazepines (BZs) allosterically modulate
g-aminobutyric acid type-A receptors (GABAARs) to
increase inhibitory synaptic strength. Diazepam
binding inhibitor (DBI) protein is a BZ site ligand ex-
pressed endogenously in the brain, but functional
evidence for BZ-mimicking positive modulatory
actions has been elusive.We demonstrate an endog-
enous potentiation of GABAergic synaptic transmis-
sion and responses toGABAuncaging in the thalamic
reticular nucleus (nRT) that is absent in both nm1054
mice, in which the Dbi gene is deleted, and mice
in which BZ binding to a3 subunit-containing
GABAARs is disrupted. Viral transduction of DBI into
nRT is sufficient to rescue the endogenous potentia-
tionofGABAergic transmission innm1054mice.Both
mutations enhance thalamocortical spike-and-wave
discharges characteristic of absence epilepsy.
Together, these results indicate that DBI mediates
endogenous nucleus-specific BZ-mimicking (‘‘endo-
zepine’’) roles to modulate nRT function and sup-
press thalamocortical oscillations. Enhanced DBI
signaling might serve as a therapy for epilepsy and
other neurological disorders.
INTRODUCTION
Allosteric modulation can profoundly regulate the function of ion
channels and G protein-coupled receptors in either a positive or
negative direction (Conigrave and Franks, 2003; Schwartz and
Holst, 2007) and is of increasing interest for both physiology
and pharmacology. Benzodiazepines (BZs) act as allosteric
modulators on type-A receptors for the inhibitory neurotrans-
mitter g-aminobutyric acid (GABA). BZs act as either positive
allosteric modulators (PAMs) and prolong currents through
GABAARs to increase the duration and strength of inhibitory
signals, or as negative allosteric modulators (NAMs, or in-
verse agonists) (Sieghart, 1995). The discovery of BZ sites onGABAARs (Braestrup and Squires, 1977; Mo¨hler and Okada,
1977; Gavish and Snyder, 1980) led to the hypothesis that the
brain might synthesize its own endogenous BZ site ligands
(Iversen, 1977). In the intervening years, however, functional
evidence for endogenous PAM effects has been quite elusive.
The family of peptides derived from the 10 kDa protein
diazepam binding inhibitor (DBI) (Guidotti et al., 1983; Alho
et al., 1985), also known as acyl-CoA binding protein (ACBP)
(Knudsen, 1991), has been suggested to play such roles. Most
evidence, however, has indicated NAM actions, such as facilita-
tion of anxiety behaviors (Guidotti et al., 1983; De Mateos-
Verchere et al., 1998), increased aggression (Kavaliers and Hirst,
1986), and decreased sleep (Dong et al., 1999). DBI and a DBI
fragment peptide, octadecaneuropeptide (ODN), also promote
neurogenesis in the subventricular zone (SVZ) via negative
modulation of GABA signaling (Alfonso et al., 2012). DBI is
synthesized by both neurons and glia (Alho et al., 1989), and
its proteolytic peptide products bind to both GABAAR and mito-
chondrial BZ sites (Papadopoulos et al., 1991). Functional
evidence for endogenous PAM actions that would suppress
neural excitability, however, has not been demonstrated.
Absence seizures, which are characterized by staring spells
and brief lapses of consciousness that occur hundreds of times
per day, are driven by abnormal oscillatory activity in thalamo-
cortical (TC) networks (Crunelli and Leresche, 2002; Beenhakker
and Huguenard, 2009). The thalamic reticular nucleus (nRT) is
functionally and anatomically poised to play a critical gating
role in this circuitry, which is normally involved in sleep rhythms
and sensory processing (Steriade et al., 1993). nRT receives
excitatory input from both corticothalamic and TC axons and
provides GABAergic input onto TC relay cells in dorsal thalamus,
such as the ventrobasal nucleus (VB), as well as intranuclear
inhibition via recurrent collaterals (Cox et al., 1996; Pinault
et al., 1997; Shu and McCormick, 2002). Reductions in intra-
nRT inhibition result in hypersynchronous epileptiform oscilla-
tions between nRT and VB and promote absence seizures (von
Krosigk et al., 1993; Huguenard and Prince, 1994a; Huntsman
et al., 1999; Sohal and Huguenard, 2003). Conversely, a gain of
intra-nRT inhibition dampens oscillatory duration and power
(Schofield et al., 2009). Modulation of intra-nRT inhibition can
thus shape TC circuit activity, thereby influencing seizure
susceptibility and duration.Neuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc. 1063
Figure 1. Effects of a3(H126R) Mutation on nRT IPSCs and Responses to Laser Photolysis of Caged GABA
(A) Averaged sIPSCs from all nRT cells recorded from wild-type (n = 23 cells) and a3(H126R) mice (n = 20 cells) at P4–14, normalized to peak amplitude.
(B) Probability distributions for >1,500 events/group comparing sIPSC half width in WT versus a3(H126R).
(C) Averaged eIPSC traces across all nRT cells recorded from WT mice (black trace) and a3(H126R) mutant mice (blue trace) at P14–21, normalized to peak
amplitude. Black dot indicates time of electrical stimulation applied to nRT (stimulus artifact removed for clarity).
(D) Mean + SEM for eIPSC half width in WT (black bar, n = 22 cells) and a3(H126R) mutant mice (blue bar, n = 10 cells).
(E) Mean amplitude versus mean variance of sIPSCs from example WT (black) and a3(H126R) (blue) nRT cells. The curve fit is to the parabolic function:
s2-s2Noise = iIm  I2m/N.
(F and G) Mean + SEM for unitary conductance (g) (F, p > 0.8) and number of channels mediating sIPSC events (G, p > 0.4).
(H) Averaged uncaged IPSC traces for nRT patches fromWT (black trace, n = 8 patches) and a3(H126R) mutant mice (blue trace, n = 5 patches) at P21. hn symbol
indicates time of 1 ms UV laser stimulus.
(I and J)Mean + SEM for uncaged IPSC half width (I; p > 0.5) and 90%–10%decay time (J; p > 0.3). Note that in contrast to the sniffer patch experiments presented
in Figure 5, here the patches were positioned in the superfusion solution > 100 mm above the slice to eliminate the influence of endogenous modulators.
**p < 0.01, ***p < 0.001 versus WT. See also Figure S1 and Table S1.
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Endogenous Potentiation of GABAA Receptors by DbiIn mature nRT, the predominant GABAAR a subunit is a3,
whereas a1 is highly expressed in dorsal thalamus (Wisden
et al., 1992; Fritschy and Mohler, 1995). Experiments utilizing
mice bearing point mutations in either a3 (a3[H126R]) or a1 sub-
units (a1[H101R]) that selectively abolish BZ binding in GABAARs
containing these subunits (Rudolph et al., 1999; Lo¨w et al., 2000)
demonstrated that BZs act via specific enhancement of intra-
nRT inhibition to suppress TC oscillations (Sohal et al., 2003).
A human GABAAR g2 subunit mutation that alters BZ binding
is associated with absence seizures (Wallace et al., 2001), sug-
gesting a role for a PAM in regulating seizure activity, but this
mutation also affects receptor trafficking (Kang and Macdonald,
2004) and GABA deactivation and desensitization kinetics
(Bowser et al., 2002).
DBI mRNA is widely expressed throughout the brain, including
the thalamus (Lein et al., 2007). Previous immunohistochemical
studies have observed varying profiles of protein expression
for DBI and fragment peptides in the CNS of various species
(Tonon et al., 1990; Slobodyansky et al., 1992; Lihrmann et al.,
1994), likely due to use of different antisera and other methodo-
logical differences, but in some cases higher expression was
observed in nRT (Alho et al., 1985, 1989). We therefore hypoth-
esized that DBI may exert endogenous effects within the thal-
amus, thereby modulating seizure susceptibility. Here, we inves-1064 Neuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc.tigate this by comparing inhibitory transmission, effects of
BZ site blockade, and seizure profiles in wild-type (WT),
a3(H126R), and nm1054 (newmutation 1054)mice, which harbor
a 400 kb deletion on chromosome 1 that includes the Dbi gene
(Ohgami et al., 2005). Furthermore, we tested the ability of viral
transduction of DBI into the thalamus to rescue the effect of
the nm1054 mutation. We also examine allosteric modulation
of responses to focal GABA uncaging in ‘‘sniffer’’ patches pulled
from VB neurons and placed back in the slice in either VB or nRT.
Our results provide novel functional evidence for the constitutive
presence of endogenous BZ binding site ligands (‘‘endoze-
pines’’) that mimic the PAM actions of BZs specifically
within nRT.
RESULTS
IPSC Duration in nRT Is Reduced in a3(H126R) Mutant
Mice
The primary PAM effect of BZs on GABAARs is to increase the
duration of inhibitory postsynaptic currents (IPSCs) (Mody
et al., 1994). Therefore, we focused on this parameter in assess-
ing whether endogenous BZ site PAMs alter intrathalamic inhibi-
tion. We recorded spontaneous IPSCs (sIPSCs) and evoked
monosynaptic intra-nRT IPSCs (eIPSCs) in nRT cells from
Figure 2. Flumazenil Shortens IPSCDuration in nRT, but Not VB, and
This Effect Depends on the a3 Subunit BZ Binding Site
(A) Representative traces recorded in individual nRT and VB cells before and
during FLZ treatment.
(B) Averaged sIPSCs in individual nRT and VB cells before and during FLZ
treatment, normalized to peak amplitude.
(C) sIPSC half width in nRT (n = 13) and VB (n = 17) cells before (Con) and during
FLZ treatment at P4–14. Open boxes indicate mean ± SEM.
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Endogenous Potentiation of GABAA Receptors by DbiC57BL/6WT and a3(H126R) mice. As in previous reports (Hunts-
man and Huguenard, 2000), sIPSC duration progressively
decreased through early development, reaching maturity by
P20; therefore, all experiments used age-matched comparisons.
a3(H126R) cells in both young and adult mice showed briefer
sIPSCs (p < 0.001) and eIPSCs (p < 0.01) compared to WT (Fig-
ures 1A–1D and S1; Table S1). The decay phase of sIPSCs could
be best described by a double exponential function, and both
fast and slow decay time constants were shortened by the
a3(H126R) mutation, while the relative contribution of fast and
slow decay was unaffected (Table S1). This suggests that both
components of IPSC decay are dependent on BZ-sensitive
GABAARs. There was no difference in unitary conductance or
numbers of channels mediating events as revealed by non-
stationary variance analysis (Sigworth, 1980; De Koninck and
Mody, 1994; Schofield and Huguenard, 2007; Figures 1E–
1G). Outside-out membrane patches pulled from WT and
a3(H126R) cells showed similar responses to laser photolysis
of caged GABA (1 mM) (Figures 1H–1J), indicating that differ-
ences in sIPSC duration are not due to altered GABA affinity or
chloride conductance, but rather are due to the modulatory
actions of a constitutively released BZ site PAM.
Flumazenil Reduces IPSC Duration in nRT, but Not VB
To test the hypothesis that in WT mice an endogenous BZ site
PAM constitutively potentiates IPSC duration, we examined
the effect of 10 min bath application of flumazenil (FLZ, 1 mM),
a BZ site antagonist (Hunkeler et al., 1981). FLZ reduced sIPSC
(p < 0.001) and eIPSC (p < 0.05) duration, along with decay
rates, inWT nRT cells (Figures 2A–2E; Table S1) but had no effect
on sIPSC duration in a3(H126R) cells (Figures 2F and 2G), con-
firming that these effects depend on the BZ site on the a3
subunit.
BZs and DBI-derived peptides can increase the production of
neurosteroids via upregulation of the mitochondrial BZ receptor,
also known as peripheral BZ receptor (PBR) or 18 kDa trans-
locator protein (TSPO) (Papadopoulos et al., 1991; Tokuda
et al., 2010). To examine if the FLZ-sensitive potentiation of
sIPSCs reflect actions of neurosteroids, we used the 5a-reduc-
tase inhibitor finasteride (1 mM) to block neurosteroidogenesis.
Finasteride alone reduced nRT sIPSC duration, indicating a level
of constitutive neurosteroid expression (Figures 3A and 3B), but
did not affect the response to FLZ, indicating that FLZ-induced
reductions in sIPSC duration do not reflect blockade of neuro-
steroid actions (Figures 3C and 3D).
The degree of constitutive BZ site activation in nRT was esti-
mated at 60%, based on the maximal modulation produced
by a saturating concentration (100 nM) of clonazepam (CZP)(D) Averaged eIPSC traces in a representative nRT cell before (Control, black
trace) and during FLZ treatment (FLZ, red trace).
(E) eIPSC half width in individualWT nRT cells (n = 8) before (Con), during (FLZ),
and after (Wash) FLZ treatment recorded at P19–22. Open boxes indicate
mean ± SEM during control, FLZ, and washout conditions.
(F) Averaged traces of sIPSCs recorded in a representative a3(H126R) nRT cell
before and during FLZ treatment, normalized to peak amplitude.
(G) sIPSC half width in a3(H126R) nRT cells (n = 10) before (Con) and during
FLZ treatment at P4–14. Open boxes indicate mean ± SEM.
*p < 0.05, ***p < 0.001 versus con. See also Figure S2 and Table S1.
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Figure 4. Constitutive Activation of BZ Sites in nRT Is Approximately
60% of Maximal, and VB Neurons Are Sensitive to BZs
(A) Representative averaged traces of sIPSCs recorded in an individual WT
nRT cell under control conditions (black trace), after 10 min bath application of
100 nM clonazepam (CZP, gray trace), and in CZP with subsequent 10 min
bath application of FLZ (CZP+FLZ, red trace), normalized to peak amplitude.
(B) sIPSC half width in individual WT nRT cells (n = 8) at P20–29 in control
conditions (Con), during CZP treatment (CZP), and during subsequent FLZ
treatment (CZP+FLZ). Open boxes indicate mean ± SEM during control
(black), CZP (gray), and CZP+FLZ conditions (red).
(C)Mean + SEM for percentage change in sIPSC half width from control to CZP
conditions (gray bar), CZP to CZP+FLZ conditions (red bar), and from control
to CZP+FLZ conditions (black bar).
(D) Mean + SEM for the within-cell ratio of the percentage change from control
to CZP+FLZ conditions compared to the percentage change from CZP alone
to CZP+FLZ.
(E) Averaged sIPSC traces from control VB cells (black trace) and cells in slices
either preincubated in 100 nM clonazepam (CZP, gray trace), or in CZP with
subsequent 10 min bath application of FLZ (CZP+FLZ, red trace). Note that
FLZ treatment does not reduce sIPSC duration past control values, as
compared to nRT cells.
(F) Probability distribution for >800 events per group comparing sIPSC
half width in control (black line, n = 8) and CZP-preincubated cells (gray line,
n = 11).
**p < 0.01, ***p < 0.001 versus control (B and F), ###p < 0.001 versus CZP (B).
Figure 3. Endozepine Effects in nRT Are Distinct from Neurosteroid
Actions
(A) Averaged sIPSC traces from nRT cells in control conditions (n = 14 cells)
and cells preincubated and recorded in finasteride (n = 13 cells) recorded at
ages P17–25, normalized to peak amplitude.
(B) Probability distributions for >1,300 events per group comparing sIPSC half
width in control (black line) versus finasteride conditions (purple line).
(C) sIPSC half width in individual nRT cells in control (n = 10) or finasteride
conditions (n = 9) before (Con) and during (FLZ) in vitro FLZ treatment. Open
boxes indicate mean ± SEM.
(D) Mean + SEM for percentage change in sIPSC half width in response to FLZ
in control and finasteride conditions.
**p < 0.01, ***p < 0.001 versus control (B and C); ns, not significant.
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cell sIPSCs (p > 0.2) (Figures 2A–2C and S2) but reversed
the effects of CZP (Figures 4E and 4F), indicating that VB
neurons do respond to FLZ, but only in the presence of exoge-
nous BZs; i.e., endogenous BZ site PAMs are not functionally
active in VB.
Dbi Gene Products Mediate Endogenous BZ-Mimicking
Actions in nRT
One molecular candidate that may mediate the endogenous
PAM effects in nRT is DBI. To test the role of DBI in mediating
these effects, we compared nm1054 mice to WT littermates.
Immunocytochemical staining confirmed that DBI protein
expression in the thalamus is essentially abolished in nm1054
mice (Figures 5A and 5B). As with the a3(H126R) mutation, the
duration, charge transfer, and fast and slow decay time con-
stants of sIPSCs in nRT cells from nm1054 mice was reduced
compared to WT (p < 0.001) (Figures 5C and 5D; Table S2).
These results suggest that loss of the Dbi gene reduces endog-
enous allosteric potentiation of GABAergic currents in nRT.1066 Neuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc.
Figure 5. AAV-Mediated Expression of DBI Rescues Effects of nm1054 Mutation on nRT sIPSC Duration
(A and B) Fluorescence images illustrating immunocytochemical staining for DBI and the nucleic acidmarker DAPI in striatum and thalamus inWT (A) and nm1054
(B) mice. Dotted and dashed lines indicate approximate borders of striatum (Str), internal capsule (IC), and thalamic nuclei.
(C) Averaged sIPSCs from nRT cells recorded from WT (n = 14 cells) and nm1054 mice (n = 13 cells) at P22–29, normalized to peak amplitude.
(D) Probability distributions (>1,300 events/group) comparing sIPSC half width.
(E) GFP fluorescence in mouse thalamus injected with AAV-DBI-GFP vector.
(F–H) DBI and GFP staining in nRT of nm1054 mice injected with control AAV-GFP (F) or AAV-DBI-GFP vector (G and H).
(I) Probability distributions (>800 events/group) comparing sIPSC half width.
(J) sIPSC half width in nRT cells from WT mice injected with control AAV-GFP (left, n = 7 cells), and nm1054 mice injected with AAV-GFP (middle, n = 7) or
AAV-DBI-GFP vector (right, n = 11) before (Con) and during FLZ treatment. Open boxes indicate mean ± SEM.
(K) Mean + SEM for percentage change in sIPSC half width in response to FLZ.
Calibration: 100 mm (A and B); 200 mm (E); 25 mm (F–H). **p < 0.01, ***p < 0.001 versus WT (D, I, and K) or Con (J); ##p < 0.01, ###p < 0.001 versus nm1054
AAV-DBI-GFP (I and K). See also Figure S3 and Table S2.
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to loss ofDbi gene products, we tested the effect of infecting nRT
cells with an AAV vector expressing DBI and green fluorescent
protein (GFP) (Figure S3). Injection of AAV-DBI-GFP into nRT of
nm1054 mice both increased sIPSC duration and conferred
responsiveness to FLZ treatment that was not observed in
nm1054mice injected with control AAV-GFP (Figures 5E–5K). In-
jection of AAV-GFP into WT nRT was confirmed to not affect
responsiveness to FLZ (Figures 5I–5K). Thus the endogenous
PAM actions in nRT are mediated by products of the Dbi gene.GABA Uncaging Responses in Sniffer Patches Pulled
from VB Neurons Demonstrate nRT-Dependent
Potentiation
The nucleus-specificity of FLZ effects may result from differen-
tial localization of PAMs and/or different GABAAR subunit
composition in nRT and VB. To test these possibilities directly,
we pulled outside-out membrane patches containing GABAARs
from VB cells, which were then placed back into the slice to
function as ‘‘sniffer patches’’ (Isaacson et al., 1993; Allen,
1997; Banks and Pearce, 2000). We then tested the responseNeuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc. 1067
Figure 6. GABAARs from VB Neurons Respond to Endozepine
Modulation When Placed in nRT
(A) Uncaged GABA IPSC responses averaged across all outside-out patches
pulled from VB neurons recorded when patches were placed in VB or nRT,
normalized to peak amplitude. Inset, proof-of-principle experiment demon-
strating potentiation of averaged responses recorded from the same patch
first placed in VB (1) and thenmoved to nRT (2), normalized to peak amplitude.
Similar results were obtained in three other patches.
(B) Responses averaged across all WT patches in the presence of FLZ,
normalized to peak amplitude.
(C) Responses averaged across all patches recorded in slices from nm1054
mice, normalized to peak amplitude. Inset, schematic illustrating movement of
patch pipette from VB to nRT.
(D) Responses averaged across all nm1054 patches in the presence of FLZ,
normalized to peak amplitude. Inset, averaged traces for responses recorded
when patches were placed in nRT, replotted from (A)–(D) for clarity.
(E) Mean + SEM for 90%–10% decay time of responses. Colored bars for
patches placed in nRT are all significantly different fromWT control, but are not
significantly different from each other (p > 0.9). Each bar represents 6–8
patches. There was no difference for patches in VB (p > 0.8). FIN, finasteride.
hn symbol, 1 ms laser stimulus.
*p < 0.05, ***p < 0.001 versus respective values for patches placed in VB;
##p < 0.01 versus WT in nRT. See also Figure S4.
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Endogenous Potentiation of GABAA Receptors by Dbiof these patches to laser photolysis of caged GABA (100 mM)
when placed 25–50 mm deep into the slice in either VB or
nRT (Figure 6).1068 Neuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc.In WT slices, sniffer patches moved to nRT exhibited an
increased uncaged IPSC duration compared to patches placed
in VB (p < 0.00001) (Figure 6A). Both FLZ treatment and the
nm1054 mutation largely blocked the nRT-dependent potentia-
tion (25% enhancement remaining in FLZ or nm1054 versus
72% in control, p < 0.01), and FLZ had no effect on responses
in nm1054 slices (p > 0.9), suggesting that the nm1054mutation
removes a source of potentiating actions at BZ sites. This was
confirmed further by occlusion of the nRT-dependent potentia-
tion to a similar degree (13% potentiation remaining) by the
presence of CZP (Figures S4A and S4B). Combined application
of GABA transporter (GAT) antagonists and FLZ in WT slices
blocked all nRT-dependent potentiation (p > 0.9), whichwas pre-
served in the presence of GAT antagonists alone (p < 0.001) (Fig-
ures S4C–S4E), demonstrating that the residual potentiation in
the presence of FLZ/CZP and in nm1054 mutants results from
tissue-dependent differences in GABA uptake. Dbi gene prod-
ucts that are endogenous PAMs are thus constitutively released
and bind to the extracellular BZ binding domain on GABAA
receptors in nRT, but not VB. Furthermore, a1-containing
GABAARs in VB are sensitive to endogenous PAMs (i.e., these
actions do not depend on a3 subunits per se) but do not normally
respond to FLZ treatment due to the absence of endogenous
ligand in this nucleus.
Altered Spike-and-Wave Discharge Activity
in a3(H126R) and nm1054 Mice
Intra-nRT inhibition plays a critical role in regulating thalamic
oscillations and absence seizure activity in the thalamocortical
circuit. To examine whether the endogenous PAM actions
observed in nRT modulate seizure susceptibility, we performed
electroencephalogram (EEG) recordings in adult mice and
assessed both spontaneous and pharmacologically induced
spike-and-wave discharges (SWDs, a characteristic of absence
epilepsy). SWDs in human absence epilepsy patients typically
display 3 Hz internal frequency (Steriade et al., 1993; Crunelli
and Leresche, 2002), but in many rodent models the internal
frequency is in the range of 4–6 Hz (Noebels and Sidman,
1979; Ryan and Sharpless, 1979; Hosford et al., 1992). Both
a3(H126R) and nm1054 mice showed a higher incidence of
spontaneous 4–6 Hz SWDs compared to the very rare events
in WT counterparts (p < 0.01; Figures 7A–7D), suggesting a level
of constitutive BZ site activation that is antiepileptic.
Low dose pentylenetetrazol (PTZ) is a common means of
chemically inducing absence seizures and SWD in rodents
(Snead, 1998). In WT and a3(H126R) mice on the C57BL/6
background, however, PTZ induced generalized tonic-clonic
seizures rather than absence seizures, precluding examination
of strain-dependent differences in SWDs (see Supplemental
Information). Therefore, we also examined a3(H126R) mutants
on the 129X1/SvJ background, which we found to be less sus-
ceptible to tonic-clonic seizures. In this strain, experimental
absence seizures initiated rapidly and were characterized by
prominent4–5 Hz SWDs that peaked approximately 5min after
injection, reaching a similar peak incidence in both genotypes,
but persisted at a much higher rate over time in the a3(H126R)
mutants (Figure S5). SWD internal frequency showed a progres-
sive slowing from 4 to 3 Hz during the course of repeated
Figure 7. Endozepines Modulate Spike-and-Wave Discharge (SWD) Activity Characteristic of Absence Seizures In Vivo
(A and B) Example traces of spontaneous SWDs recorded from a3(H126R) mice and respective WT (A) and nm1054mice and respective WT (B). Note that SWD
amplitude (power) was not significantly different between groups (p > 0.2). Therefore, examples were chosen to illustrate typical SWD waveforms in each
condition, which were not affected by SWD power.
(C and D) Mean + SEM for spontaneous 4-6 Hz SWD rate and percentage of time spent in spontaneous SWD activity in WT (n = 17) and a3(H126R) mice (n = 9) (C)
and WT (n = 7) and nm1054 mice (n = 4) (D).
(E and F) Mean ± SEM for SWD period over time following PTZ injection (Time 0, 40mg/kg) in WT (n = 7) and a3(H126R) mice (n = 4) (E) andWT (n = 7) and nm1054
mice (n = 4) (F).
(G andH) Linear regression of lines of best fit for points plotted in (E-F) shows positive correlations (i.e., SWD slowing) with time after PTZ injection inWT, but not in
a3(H126R) nor nm1054 mice.
**p < 0.01, ***p < 0.001 versus WT; ##p < 0.01, ###p < 0.001, repeated-measures ANOVA (E and F) or Pearson correlation (G and H) across 1 min bins after PTZ
injection. Gray bars in (E) and (F) indicate times at which values differed between mutants and controls (p < 0.05). See also Figure S5.
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mutants (p > 0.8) (Figures 7E and 7G). Similarly, nm1054 mice
failed to display the slowing of SWD internal frequency following
PTZ injection (p > 0.6) that was observed in WT (Figures 7F and
7H). These results suggest that PAM release within the TC circuit
reduces seizure susceptibility and severity through a slowing of
the seizure oscillations, which may destabilize them.
DISCUSSION
Following the discovery of BZ binding sites on GABAARs 35
years ago (Braestrup and Squires, 1977; Mo¨hler and Okada,
1977; Gavish and Snyder, 1980), it was thought that the brain
likely produces cognate endogenous ligands for these sites. In
the intervening years, however, the search for an endogenous
PAM proved elusive. The studies presented here provide func-
tional evidence for endogenous BZ-mimicking (‘‘endozepine’’)
PAM actions and indicate that these effects are mediated by
Dbi gene products. This was demonstrated by the deficits in
IPSC potentiation exhibited in nm1054mice, which was rescued
by local viral transduction of DBI into nRT. Although the PAM
effects in nRT depend on the a3 subunit BZ binding site, as
demonstrated by the lack of modulation in a3(H126R) mice,GABAARs in VB neurons respond to endozepines when placed
in nRT. This indicates that the nucleus specificity of the observed
effects results from nRT-specific localization of PAMs within the
thalamus. Finally, we present in vivo evidence that SWD activity
is altered in both a3(H126R) and nm1054 mice, suggesting that
local PAM actions in nRT can exert seizure-suppressive effects
on TC circuitry as a whole. Although it remains to be determined
whether DBI itself or a peptide fragment act as the BZ site
agonist, our data provide functional evidence that indeed
peptides in the DBI family can act as PAMs.
Constitutive Endogenous Positive Allosteric Modulation
of GABAergic Transmission by Endozepines in nRT
The principal findings of this study are the existence and
functional consequences of endozepines in nRT, which act to
potentiate GABAergic postsynaptic currents in this nucleus.
a3(H126R) mutant mice, in which classical BZ binding to the
GABAAR a3 subunit is effectively abolished (Lo¨w et al., 2000),
exhibited shorter durations of both sIPSCs and eIPSCs, indi-
cating that in WT mice, constitutive modulation via this binding
site acts to prolong inhibitory signals. Another GABAAR muta-
tion associated with BZ binding and absence seizures (Wallace
et al., 2001) has been reported to affect basic receptorNeuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc. 1069
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response to GABA (Bowser et al., 2002; Kang and Macdonald,
2004). Here, the effects of the a3(H126R) mutation on sIPSCs
were confined to the duration of events, with no difference in
either amplitude or frequency; thus it does not appear that
this mutation leads to large differences in receptor expression,
localization, or function besides the loss of BZ or endozepine
binding. Both fast and slow decay time constants were
reduced, suggesting that both b1 and b3 subunit-containing re-
ceptors in nRT are responsive to endozepines (Huntsman and
Huguenard, 2006; Hentschke et al., 2009). Furthermore, when
nRT GABAARs in excised patches were removed from the slice
and thus no longer exposed to putative endogenous modula-
tors within the slice, the response to GABA uncaging was
identical between WT and a3(H126R) mutant mice. Together,
these results support the interpretation that the H126R mutation
does not lead to differences in fundamental receptor properties
apart from the effects on BZ/endozepine binding in a3(H126R)
mutant receptors.
The ability of FLZ, a BZ binding site antagonist (Hunkeler et al.,
1981), to reduce sIPSC duration also suggested an endogenous
augmentation of IPSC duration in nRT. Similarly, FLZ has been
observed to reduce evoked inhibitory postsynaptic potential
(IPSP) amplitude in hippocampal CA1 pyramidal neurons (King
et al., 1985) and eIPSC duration in dissociated cortical neurons
(Vicini et al., 1986). Some reports have indicated agonist effects
of FLZ (Skerritt and Macdonald, 1983; De Deyn and Macdonald,
1987; Weiss et al., 2002), including at receptors carrying a3 sub-
units (Ramerstorfer et al., 2010). This would not explain the
reductions in duration and decay time observed here, although
FLZ increased sIPSC amplitude and slightly increased charge
transfer in both WT and a3(H126R) nRT cells, potentially indi-
cating a nonspecific effect representing actions on presynaptic
terminals (Table S1). Partial agonistic effects of FLZ have also
been described at receptors containing a4 or a6 subunits (i.e.,
receptors that do not respond to classical BZs) (Hadingham
et al., 1996; Knoflach et al., 1996; Whittemore et al., 1996).
Here, however, a3(H126R) GABAARs did not respond to FLZ,
indicating that disruption of BZ binding to these receptors
does not change the direction of response to BZ binding site
activation.
A recent report indicates that the CSF of hypersomnolent
patients can potentiate currents evoked by GABA application
in a FLZ-sensitive manner (Rye et al., 2012). This potentiation,
however, is not occluded by the BZ midazolam and persists in
a1(H101R) GABAARs, indicating that it does not represent a
true BZ-mimicking endozepine effect.
Dbi Gene Products Mediate Endozepine Effects in nRT
The experiments in a3(H126R) mice examined the potential
effects of endozepines at the level of postsynaptic GABAARs.
To investigate this question at the level of the ligand, we tested
the role of Dbi gene products in mediating endozepine actions
by exploring intra-nRT GABAergic transmission in nm1054
mice, which lack the Dbi gene (Ohgami et al., 2005). The other
known genes deleted by the mutation are: primary ciliary dyski-
nesia protein 1 (Pcdp1); secretin receptor (Sctr); neuronal
voltage-gated calcium channel g-like subunit (Pr1); and six-1070 Neuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc.transmembrane epithelial antigen of the prostate 3 (Steap3)
(Ohgami et al., 2005; Lee et al., 2007). Pr1 transcript is either
absent or very low in mouse thalamus (Lein et al., 2007). The
other genes are not expected to affect postsynaptic GABAA
receptor function, though the secretin peptide may act on pre-
synaptic terminals to increase GABAergic transmission in cere-
bellum (Yung et al., 2001). Although future work will examine
the role of DBI using a specific knockout model, nm1054 mice
injected with the AAV-DBI vector in nRT displayed the following
effects: (1) prolonged sIPSC duration compared to nm1054mice
injected with control virus, and (2) a reduction in sIPSC duration
in response to FLZ that was not observed in nm1054 mice in-
jected with control virus and is of the same magnitude as that
observed inWTmice. DBI is thus necessary and sufficient to pro-
duce the endogenous PAM effect, and is either the endogenous
modulator itself or at least a precursor.
These results stand in contrast to the majority of previous
studies of DBI-related peptides, which have primarily found
NAM effects. Application of DBI reduced the amplitude of
GABA currents recorded in cultured spinal cord neurons
(Bormann et al., 1985;Macdonald et al., 1986), as did ODN appli-
cation to nucleated outside-out patches from SVZ progenitor
cells (Alfonso et al., 2012). A NAM effect, however, would be dis-
inhibitory and would not explain the endogenous potentiation
observed here. Of note, these studies used high concentrations
(0.5–20 mM) of applied peptide. Effects of exogenous DBI pep-
tides on seizures exhibit dose-dependent effects, with low doses
being efficacious at suppressing seizures (Garcia de Mateos-
Verchere et al., 1999) and high doses promoting seizure activity
(Ferrero et al., 1986). It is also possible that nRT-specific recep-
tor-associated proteins are required to obtain a PAM effect,
though this is unlikely to be solely responsible as VB receptors
placed in nRT also exhibit a PAM response, as demonstrated
in the sniffer patch studies (Figure 6). In addition, the dose
response curve for stimulation of intracellular calcium levels in
cultured astrocytes by ODN and octapeptide (OP), a smaller
fragment, is bell-shaped with peak stimulation at 10 nM
(Leprince et al., 1998). Therefore, it is possible that extracellular
concentrations of endogenous DBI peptides in discrete areas
such as nRT are at a lower level that is more likely to exert
PAM rather than NAM effects.
In contrast to the stark nRT versus VB differences in physiolog-
ical PAMeffects of DBI, immunoreactivity to DBIwas observed in
both nRT and VB (Figure 5). In this regard, it is important to note
that DBI is also known as ACBP and the Dbi/Acbp gene is
thought to ubiquitously serve housekeeping functions (Knudsen
et al., 1993), generating an intracellular protein critically involved
in facilitating intracellular transport of Acyl-CoA. We hypothesize
that the nRT versus VB differences in the electrophysiological
findings likely represent nucleus-specific differences in the
extracellular release and processing of DBI.
In the current studies, we used a viral strategy to examine
whether Dbi gene products are necessary and sufficient to pro-
duce endozepine actions in nRT. Although it is possible that viral
introduction of DBI into a system in this way induces changes in
its modulatory effects, it is unlikely that this explains the PAM
actions observed here, as a recent report using similar viral vec-
tors to express DBI and ODN in the SVZ exclusively observed
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these differences remain to be determined, though one possible
explanation is differential intra- or extracellular processing of
DBI, the nature of which is specific to certain areas or cell types.
It is certainly conceivable that some DBI fragments exert PAM
effects, whereas others are NAMs. In addition, preliminary evi-
dence suggests that exogenous application of DBI does not alter
sIPSCs in VB (C.A.C. and J.R.H., unpublished data), in contrast
to the robust potentiation of uncaging responses when VB sniffer
patches are placed in nRT. This further supports a working
model in which nRT-specific processing of Dbi gene products
underlies the PAM actions.
Functional Endozepines Are Absent in VB
Strikingly, endogenous BZ-mimicking potentiation was ob-
served in nRT, but not in adjacent VB thalamus. This raises the
question of why such effects would be specifically localized to
nRT, and not VB. Perhaps selection pressure led to evolution
of an adaptive specific subcircuit modulation in nRT that reduces
the possibility of seizure occurrence. Synaptic inhibition in nRT
exerts a prominent desynchronizing effect to reduce the propen-
sity for oscillatory activity (von Krosigk et al., 1993; Huntsman
et al., 1999; Schofield et al., 2009), and potentiation of synaptic
inhibition by BZs further suppresses oscillations (Huguenard
and Prince, 1994a; Sohal and Huguenard, 2003; Sohal et al.,
2003). In VB, by contrast, postsynaptic inhibition via GABAA
and GABAB receptors interacts with prominent T-type calcium
conductances in VB relay neurons to drive robust postinhibitory
rebound burst firing (Llina´s and Jahnsen, 1982; Huguenard and
Prince, 1994b; Sohal and Huguenard, 2003) and paradoxically
promote oscillatory activity. Therefore, endogenous potentiation
of intra-nRT inhibition is poised to exert an endogenous antio-
scillatory seizure-suppressing effect, whereas such potentiation
in VB could be disadvantageous. It should be noted, however,
that VB neurons are BZ-sensitive, as demonstrated here and in
previous studies (Oh et al., 1995; Peden et al., 2008), although
systemic treatment with BZs would influence both nRT and VB
inhibition such that activity throughout the circuit would be
globally suppressed. Indeed, constitutive activation in nRT was
60% of maximal, indicating that although there is a substantial
degree of endogenous modulation, there is still an extent of
enhancement that can be exploited by exogenous BZs, likely
explaining the therapeutic efficacy of these drugs.
Focal GABA Uncaging on Sniffer Patches Reveals
Nucleus-Specific Differences in Endozepine
Potentiation and GABA Uptake
Here, we introduce amethodology combining the ‘‘sniffer patch’’
recording configuration (Isaacson et al., 1993; Allen, 1997;
Banks and Pearce, 2000) with laser GABA uncaging, which is
used to examine nucleus-specific differences in endogenous
BZ site modulation. The main advantage of this method is that
GABA exposure to the patches can be normalized independent
of patch placement, so that region-specific differences in
modulation of GABAergic signaling can be assessed. Combined
application of GAT antagonists and FLZ was sufficient to
completely block the nRT-dependent potentiation. This potenti-
ation is thus mediated in large part by endozepines, and to alesser extent by nucleus-specific differences in rates of GABA
uptake, with more robust uptake in VB than in nRT. This is
consistent with the postulated role for GATs in removing GABA
from VB extracellular space in order to prevent excessive
GABABR activation and oscillatory seizure activity (Beenhakker
and Huguenard, 2010).
The durations of uncaging responses for both nRT and VB
patches are longer than those for spontaneous or evoked IPSCs,
in accordance with previous studies on patches from thalamic,
hippocampal, and cortical neurons (Galarreta and Hestrin,
1997; Jones and Westbrook, 1997; Banks and Pearce, 2000;
Schofield and Huguenard, 2007). Therefore, this appears to be
an effect of the pulled patch configuration rather than the use
of uncaging to apply GABA. Nevertheless, the application of
GABA by laser photolysis replicates the nRT versus VB differ-
ences in receptor affinity for GABA and kinetics of IPSC decay
(Zhang et al., 1997; Mozrzymas et al., 2007; Schofield and
Huguenard, 2007).
Endozepines Modulate TC Circuit Activity In Vivo
Potentiation of intra-nRT GABAergic transmission by BZs is
capable of exerting powerful antioscillatory effects by reducing
synchronization in intra-thalamic networks (Huguenard and
Prince, 1994a; Huguenard, 1999; Sohal et al., 2003). Similarly,
the EEG recordings here indicate that PAM potentiation of
GABAergic transmission, presumably within nRT as observed
in vitro, can modulate in vivo rhythmic activity in TC circuitry
in a manner consistent with suppression of seizure susceptibil-
ity and severity. In particular, both a3(H126R) and nm1054mice
exhibit similar phenotypes with respect to an increased inci-
dence of spontaneous SWDs and a lack of slowing of SWD
period following PTZ treatment that is observed in WT mice.
This suggests that endogenous activation of BZ binding sites
on GABAARs containing the a3 subunit by DBI ligands in nRT
exerts two primary effects: (1) a reduction in the propensity
for the circuit to generate SWDs, and (2) a reduction in the in-
tensity and severity of absence seizures once initiated.
Although the a3 subunit is expressed in other brain regions,
including cortical layers V and VI (Pirker et al., 2000), the com-
plementary in vitro experiments implicate actions that originate
in thalamus, and specifically in nRT, in underlying these
differences.
Summary
Our results describe the molecular identification of an endoge-
nous DBI-related PAM acting via GABAAR BZ binding sites,
which may represent a novel endogenous anti-seizure mecha-
nism. The highly specific release and processing within nRT
(and presumably other restricted brain regions) may explain
why previous studies using a3(H126R) and similar knockin
mice have not observed overt phenotypes beyond those of
subtype-specific BZ actions (Rudolph and Mo¨hler, 2004). Given
the important role of nRT as a locus of control in TC circuitry,
targeted release of Dbi-derived endozepine peptides in nRT
may be fruitful in the development of therapies against absence
seizures. Furthermore, regulation of DBI release or function may
provide a safer alternative to long-term BZ administration in the
treatment of epilepsy and other neurological disorders.Neuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc. 1071
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Additional information on these methods can be found in Supplemental
Information. All procedures were approved by the Administrative Panel on
Laboratory Animal Care at Stanford University.Brain Slice Preparation
Mice were anesthetized with pentobarbital sodium and killed via decapitation
and the brain was quickly removed and placed in ice-cold oxygenated sucrose
slicing solution. Horizontal thalamic slices (250 mm thickness) were prepared
as previously described (Huguenard and Prince, 1994a). Slices were
incubated and continuously oxygenated in warm (32C) artificial cerebro-
spinal fluid for 1 hr and then transferred to room temperature (21C–23C)
for at least 15 min prior to recording.Patch-Clamp Electrophysiology
Patch-clamp recordings were made using a MultiClamp 700A amplifier with
Clampex 9.2 software. Patch pipettes were filled with a 135 mM CsCl-
based solution. To isolate GABAergic IPSCs, ionotropic glutamate
receptors were blocked with either kynurenic acid (1 mM) or a combination
of D-(-)-2-amino-5-phosphonovaleric acid (APV, 100 mM) plus 6,7-dinitroqui-
noxaline-2,3-dione (DNQX, 20 mM).IPSCs
In whole-cell recordings, membrane potential was clamped at 60 mV.
Evoked IPSCs were elicited by extracellular tungsten electrode stimulation
in nRT.GABA Uncaging
CNB-caged GABA (Invitrogen) was added to a recirculating 10–20 ml bath
solution containing APV and DNQX. Outside-out patches of membrane from
nRT or VB cells were maintained in voltage-clamp mode at a membrane
holding potential of 30 mV. Laser photolysis (DPSS Lasers) was achieved
via 1 ms ultraviolet laser exposure.EEG Recordings
EEG recordings were obtained from either metal skull screws or silver wires
implanted above the left and right frontal and parietal cerebral cortices. Exper-
imental absence seizures were induced via s.c. injection of PTZ. EEG activity
and simultaneous video were recorded for up to 90 min post-PTZ injection.Virus Injections
Bilateral stereotaxic injections of either control or DBI-expressing AAVs were
performed under isoflurane anesthesia between P48-60. Brain slices were
prepared for electrophysiology at 2–3 weeks postinjection. Infected cells
expressing GFP were visualized using epifluorescence microscopy.Data Analysis
sIPSCs were analyzed using the custom software programs wDetecta and
WinScanSelect (J.R.H.). eIPSC and uncaging recordings were analyzed using
Clampfit. EEG recordings were analyzed using a continuous wavelet transform
method in MATLAB to isolate SWD events (Schofield et al., 2009). Compari-
sons between groups were made using two-tailed independent or paired
t tests, nonparametric Mann-Whitney rank-sum tests, or one-way ANOVA
with Tukey’s post hoc means comparison tests. Cumulative probability distri-
butions were constructed using up to 100 randomly selected sIPSCs (events)
per cell and compared using two-sample Kolmogorov-Smirnov (KS) goodness
of fit tests. Differences within each genotype for EEG parameters across
different time points after PTZ injection were assessed using one-way
repeated-measures ANOVA. Statistical significance was set at p < 0.05 for
means comparisons, and p < 0.001 for KS tests.1072 Neuron 78, 1063–1074, June 19, 2013 ª2013 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.neuron.2013.04.026.
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